{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:00:19Z","timestamp":1780999219493,"version":"3.54.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82572348"],"award-info":[{"award-number":["No. 82572348"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82202210"],"award-info":[{"award-number":["No. 82202210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Institute of Cancer Research, and Guangdong Basic and Applied Basic Research Foundation","award":["No. 2024A1515011956"],"award-info":[{"award-number":["No. 2024A1515011956"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00259-026-07840-3","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:57:16Z","timestamp":1773968236000},"page":"4988-5001","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic value of [18F]FAPI-04 PET\/CT in patients with monofocal liver lesions suspicious for hepatocellular carcinoma: a prospective comparison with LI-RADS-based contrast-enhanced CT\/MRI"],"prefix":"10.1007","volume":"53","author":[{"given":"Jiucen","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengqi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rusen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0607-6300","authenticated-orcid":false,"given":"Linqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"7840_CR1","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606. https:\/\/doi.org\/10.1016\/j.jhep.2022.08.021.","journal-title":"J Hepatol"},{"key":"7840_CR2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82:315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"key":"7840_CR3","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1111\/liv.15130","volume":"42","author":"T Torimura","year":"2022","unstructured":"Torimura T, Iwamoto H. Treatment and the prognosis of hepatocellular carcinoma in Asia. Liver Int. 2022;42:2042\u201354. https:\/\/doi.org\/10.1111\/liv.15130.","journal-title":"Liver Int"},{"key":"7840_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"7840_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358\u201380. https:\/\/doi.org\/10.1002\/hep.29086.","journal-title":"Hepatology"},{"key":"7840_CR6","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.1007\/s00330-024-10846-w","volume":"34","author":"J Cao","year":"2024","unstructured":"Cao J, Shon A, Yoon L, Kamaya A, Tse JR. Diagnostic performance of CT\/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease. Eur Radiol. 2024;34:7622\u201331. https:\/\/doi.org\/10.1007\/s00330-024-10846-w.","journal-title":"Eur Radiol"},{"key":"7840_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3348\/kjr.2018.0636","volume":"20","author":"JH Kim","year":"2019","unstructured":"Kim JH, Joo I, Lee JM. Atypical Appearance of Hepatocellular Carcinoma and Its Mimickers: How to Solve Challenging Cases Using Gadoxetic Acid-Enhanced Liver Magnetic Resonance Imaging. Korean J Radiol. 2019;20:1019\u201341. https:\/\/doi.org\/10.3348\/kjr.2018.0636.","journal-title":"Korean J Radiol"},{"key":"7840_CR8","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/s0168-8278(00)80248-2","volume":"32","author":"MA Khan","year":"2000","unstructured":"Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792\u20137. https:\/\/doi.org\/10.1016\/s0168-8278(00)80248-2.","journal-title":"J Hepatol"},{"key":"7840_CR9","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.3748\/wjg.v25.i32.4682","volume":"25","author":"RC Lu","year":"2019","unstructured":"Lu RC, She B, Gao WT, Ji YH, Xu DD, Wang QS, et al. Positron-emission tomography for hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol. 2019;25:4682\u201395. https:\/\/doi.org\/10.3748\/wjg.v25.i32.4682.","journal-title":"World J Gastroenterol"},{"key":"7840_CR10","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2967\/jnumed.108.055087","volume":"49","author":"JW Park","year":"2008","unstructured":"Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11\u00a0C-acetate PET\/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med. 2008;49:1912\u201321. https:\/\/doi.org\/10.2967\/jnumed.108.055087.","journal-title":"J Nucl Med"},{"key":"7840_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1593\/neo.121850","volume":"15","author":"VJ Christiansen","year":"2013","unstructured":"Christiansen VJ, Jackson KW, Lee KN, Downs TD, McKee PA. Targeting inhibition of fibroblast activation protein-alpha and prolyl oligopeptidase activities on cells common to metastatic tumor microenvironments. Neoplasia. 2013;15:348\u201358. https:\/\/doi.org\/10.1593\/neo.121850.","journal-title":"Neoplasia"},{"key":"7840_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160\u20137. https:\/\/doi.org\/10.2967\/jnumed.120.244806.","journal-title":"J Nucl Med"},{"key":"7840_CR13","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40644-023-00626-y","volume":"23","author":"J Zhang","year":"2023","unstructured":"Zhang J, Jiang S, Li M, Xue H, Zhong X, Li S, et al. Headto-head comparison of 18F-FAPI and 18F-FDG PET\/CT in staging and therapeutic management of hepatocellular carcinoma. Cancer Imaging. 2023;23:106. https:\/\/doi.org\/10.1186\/s40644-023-00626-y.","journal-title":"Cancer Imaging"},{"key":"7840_CR14","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","volume":"50","author":"J Zhang","year":"2023","unstructured":"Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D, et al. [18F]FAPI PET\/CT in the evaluation of focal liver lesions with [18F]FDG non-avidity. Eur J Nucl Med Mol Imaging. 2023;50:937\u201350. https:\/\/doi.org\/10.1007\/s00259-022-06022-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7840_CR15","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1007\/s00259-024-07062-5","volume":"52","author":"D Zhu","year":"2025","unstructured":"Zhu D, Song S, Zou S, Kuang D, Wang D, Min X, et al. Assessment of viable tumours by [68Ga]Ga-FAPI-04 PET\/CT after local regional treatment in patients with hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2025;52:2132\u201344. https:\/\/doi.org\/10.1007\/s00259-024-07062-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7840_CR16","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.1007\/s00259-025-07273-4","volume":"52","author":"J Liang","year":"2025","unstructured":"Liang J, Weng S, Zhang J, Jiang S, Li W, Li S, et al. Diagnostic performance of [18F]FAPI-04 PET\/CT in suspected recurrent hepatocellular carcinoma: prospective comparison with contrast-enhanced CT\/MRI. Eur J Nucl Med Mol Imaging. 2025;52:3951\u201362. https:\/\/doi.org\/10.1007\/s00259-025-07273-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7840_CR17","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1148\/radiol.2018181494","volume":"289","author":"V Chernyak","year":"2018","unstructured":"Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients. Radiology. 2018;289:816\u201330. https:\/\/doi.org\/10.1148\/radiol.2018181494","journal-title":"Radiology"},{"key":"7840_CR18","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1136\/gutjnl-2019-318555","volume":"68","author":"DH Kim","year":"2019","unstructured":"Kim DH, Choi SH, Park SH, Kim KW, Byun JH, Kim SY, et al. Meta-analysis of the accuracy of Liver Imaging Reporting and Data System category 4 or 5 for diagnosing hepatocellular carcinoma. Gut. 2019;68:1719\u201321. https:\/\/doi.org\/10.1136\/gutjnl-2019-318555.","journal-title":"Gut"},{"key":"7840_CR19","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","volume":"37","author":"E Pur\u00e9","year":"2018","unstructured":"Pur\u00e9 E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343\u201357. https:\/\/doi.org\/10.1038\/s41388-018-0275-3.","journal-title":"Oncogene"},{"key":"7840_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41416-020-01172-1","volume":"124","author":"L Boulter","year":"2021","unstructured":"Boulter L, Bullock E, Mabruk Z, Brunton VG. The fibrotic and immune microenvironments as targetable drivers of metastasis. Br J Cancer. 2021;124:27\u201336. https:\/\/doi.org\/10.1038\/s41416-020-01172-1.","journal-title":"Br J Cancer"},{"key":"7840_CR21","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","volume":"48","author":"W Guo","year":"2021","unstructured":"Guo W, Pang Y, Yao L, Zhao L, Fan C, Ke J, et al. Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [68Ga]Ga-FAPI-04 PET\/CT versus MRI and [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:1604\u201317. https:\/\/doi.org\/10.1007\/s00259-020-05095-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7840_CR22","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48:1593\u2013603. https:\/\/doi.org\/10.1007\/s00259-020-05070-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7840_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s00259-021-05442-9","volume":"49","author":"F Ding","year":"2021","unstructured":"Ding F, Huang C, Liang C, Wang C, Liu J, Tang D. 68Ga-FAPI-04 vs. 18F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer. Eur J Nucl Med Mol. 2021;49:290\u2013300. https:\/\/doi.org\/10.1007\/s00259-021-05442-9.","journal-title":"Eur J Nucl Med Mol"},{"key":"7840_CR24","doi-asserted-by":"publisher","first-page":"3319","DOI":"10.1007\/s00330-021-08382-y","volume":"32","author":"J Shin","year":"2022","unstructured":"Shin J, Lee S, Hwang JA, Lee JE, Chung YE, Choi JY, et al. MRI-diagnosis of category LR-M observations in the Liver Imaging Reporting and Data System v2018: a systematic review and meta-analysis. Eur Radiol. 2022;32:3319\u201326. https:\/\/doi.org\/10.1007\/s00330-021-08382-y","journal-title":"Eur Radiol"},{"key":"7840_CR25","doi-asserted-by":"publisher","first-page":"e240916","DOI":"10.1148\/radiol.240916","volume":"314","author":"A Lyshchik","year":"2025","unstructured":"Lyshchik A, Kuon Yeng Escalante C, Siu Xiao T, Piscaglia F, Kono Y, Medellin-Kowalewski A, et al. Contrast-enhanced US of High-Risk Indeterminate Focal Liver Observations Categorized as LR-4 or LR-M at CT\/MRI. Radiology. 2025;314:e240916. https:\/\/doi.org\/10.1148\/radiol.240916.","journal-title":"Radiology"},{"key":"7840_CR26","doi-asserted-by":"publisher","first-page":"e231160","DOI":"10.1148\/radiol","volume":"310","author":"R Cannella","year":"2024","unstructured":"Cannella R, Matteini F, Dioguardi Burgio M, Sartoris R, Beaufr\u00e8re A, Calderaro J, et al. Association of LI-RADS and Histopathologic Features with Survival in Patients with Solitary Resected Hepatocellular Carcinoma. Radiology. 2024;310:e231160. https:\/\/doi.org\/10.1148\/radiol.","journal-title":"Radiology"},{"key":"7840_CR27","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.bbadis.2017.08.027","volume":"1864","author":"JC Mertens","year":"2018","unstructured":"Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol basis Dis. 2018;1864:1454\u201360. https:\/\/doi.org\/10.1016\/j.bbadis.2017.08.027.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"7840_CR28","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s00330-022-09105-7","volume":"33","author":"H Cha","year":"2023","unstructured":"Cha H, Choi JY, Park YN, Han K, Jang M, Kim MJ, et al. Comparison of imaging findings of macrotrabecular-massive hepatocellular carcinoma using CT and gadoxetic acid-enhanced MRI. Eur Radiol. 2023;33:1364\u201377. https:\/\/doi.org\/10.1007\/s00330-022-09105-7.","journal-title":"Eur Radiol"},{"key":"7840_CR29","doi-asserted-by":"publisher","first-page":"112282","DOI":"10.1016\/j.intimp.2024.112282","volume":"138","author":"H Shang","year":"2024","unstructured":"Shang H, Lu L, Fan M, Lu Y, Shi X, Lu H. Exosomal circHIF1A derived from hypoxic-induced carcinoma-associated fibroblasts promotes hepatocellular carcinoma cell malignant phenotypes and immune escape. Int Immunopharmacol. 2024;138:112282. https:\/\/doi.org\/10.1016\/j.intimp.2024.112282.","journal-title":"Int Immunopharmacol"},{"key":"7840_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","volume":"48","author":"H Chen","year":"2021","unstructured":"Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings. Eur J Nucl Med Mol Imaging. 2021;48:73\u201386. https:\/\/doi.org\/10.1007\/s00259-020-04940-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7840_CR31","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/RLU.0000000000005456","volume":"50","author":"Y Luo","year":"2025","unstructured":"Luo Y, Qin X, Liu Y. Hepatic Inflammatory Pseudotumor on 18F-FDG and 18F-FAP-42 PET\/CT. Clin Nucl Med. 2025;50:105\u20137. https:\/\/doi.org\/10.1097\/RLU.0000000000005456.","journal-title":"Clin Nucl Med"},{"key":"7840_CR32","doi-asserted-by":"publisher","first-page":"40121","DOI":"10.1002\/hep.29487","volume":"67","author":"LR Roberts","year":"2018","unstructured":"Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology. 2018;67:40121. https:\/\/doi.org\/10.1002\/hep.29487.","journal-title":"Hepatology"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07840-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07840-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T09:24:33Z","timestamp":1780997073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07840-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7840"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07840-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee, as well as the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This article does not contain any animal experiments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants (signed by participant, parent, or legal representative) included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors declare they have no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}